More Invex Therapeutics Ltd. news
Invex Therapeutics Ltd.ASX: IXC

Appendix 4D and Half year report

Feb 15, 2024 at 10:46 PM EST · Issued by Invex Therapeutics Ltd.

Filed with ASX · Feb 15, 2024 at 10:46 PM EST

On 6ix: 6ix.com/news/appendix-4d-and-half-year-report-110

Invex Therapeutics Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Invex Therapeutics Ltd. on 6ix

Story so far

  • Half Year AccountsFeb 17, 2023
  • Half Yearly Report and AccountsFeb 22, 2022

Earlier from Invex Therapeutics

  • Invex and Peptron Mutually Terminate Manufacturing AgreementDec 21, 2023
  • Invex Granted European Patent for Exenatide in HydrocephalusNov 21, 2023
  • Proposed Capital Return to Shareholders of $14.0 MillionNov 1, 2023
  • Invex issued US patent for Traumatic Brain InjuryAug 23, 2023
  • Invex to close IIH Evolve Phase III Clinical TrialAug 20, 2023

Later from Invex Therapeutics

  • ATO Class Ruling Return of CapitalMar 20, 2024
  • Invex receives R&D Tax RebateJun 21, 2024
  • Quarterly Activities Report and Appendix 4COct 7, 2024
  • Improved Neuronal Cell Survival in 3D Model of Alzheimer'sDec 15, 2024
  • Invex Receives $0.22m R&D Tax Rebate from UK GovernmentJan 19, 2025
All Invex Therapeutics news releases↗

Follow Invex Therapeutics into a list and get an email when it puts out news.

Follow Invex Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer